PAT-DX1 Significantly Improves Survival in Animal Model of Pancreatic Cancer

ASX Announcements

Patrys has today announced the publication of new data from a series of studies by our collaborators Dr James Hansen, of Yale School of Medicine and Dr Kim O’Sullivan, of Monash University, showing that PAT‑DX1 suppresses the formation of neutrophil extracellular traps (NETs), which may reduce metastasis in some cancers.

The paper, which is published in the peer-reviewed journal ImmunoHorizons, is the first study showing that PAT-DX1 may be used to regulate the formation of NETs, which are believed to contribute to immunity, inflammation and the pathophysiology of various inflammatory diseases and some cancers.

Patrys CEO and MD, Dr. James Campbell said:

“This is an unexpected and important discovery for Patrys, offering mechanistic rationale to the previously-described ability of PAT-DX1 to reduce cancer spread by metastasis, and opening the door to broader uses of deoxymabs in non-cancer indications, particularly chronic inflammatory conditions that are driven by NET formation.”

Read today’s ASX release here.

Menu